 For Appointments
617-724-5257
Fax
617-724-3166
Office Address
Massachusetts General Hospital Cancer Center
The Claire and John Bertucci Center for Genitourinary Cancers
55 Fruit Street, YAW 7
Boston, MA 02114
Clinical Interests
Prostate Cancer; Testis Cancer; Bladder Cancer
Education
PhD Degree: Duke University, Durham, NC, 1991
MD Degree: Duke University, Durham, NC, 1992
Postdoctoral Training
Residency, Internal Medicine: Brigham & Women's Hospital, Boston, MA
Fellowship, Medical Oncology: Dana Farber Cancer Institute, Boston, MA
Postdoctoral Fellowship, Massachusetts Institute of Technology, Cambridge, MA
Board Certification
Internal Medicine, 1995
Medical Oncology, 1997
Hospital Appointments
Director, The Claire & John Bertucci Center for Genitourinary Cancers
Academic Appointments
Assistant Professor of Medicine, Harvard Medical School
My Publications
Link to PubMed Database
Publications
Smith MR, Kantoff PW, Talcott J. Metastatic prostate cancer. In: Godlee F and Goldman D, editors. Clinical Evidence. London, BMJ Publishing Group 1999, Volume 1, p. 321-327.
Smith MR, Kantoff PW, Talcott J. Metastatic prostate cancer. In: Godlee F and Goldman D, editors. Clinical Evidence. London, BMJ Publishing Group 1999, Volume 1, p. 332-339.
Smith MR. GnRH agonist-induced bone loss. The Prostate Journal 1999; 1(4):161-165.
Smith MR, Garnick G. Primary hormonal therapy for prostate cancer. In: Vogelzang N, Shipley W, Scardino P, Coffey D, editors. Comprehensive Textbook of Genitourinary Oncology, 2nd edition. Baltimore: Williams and Wilkins 1999; p. 799-803.
Smith MR. PSA screening for porstate cancer: is there a benefit? IM Internal Medicine 1999; 20(3); 51-54.
Smith MR. Successful treatment of acute disseminated intravascular coagulation (DIC) from metastatic androgen-independent prostate cancer with mitoxantrone chemotherapy. J Urology 2000; 163(1):248.
Mueller E, Smith MR, Kaufman D, Oh W, Spiegelman B, Kantoff PW. Effects of ligand activation of peroxisome proliferator activated receptor-gamma (PPAR on human prostate cancer. Proc Natl Acad Sci USA. 2000 Sep 26;97:10990-5.
Smith MR, Kaufman D, Guerin K, Oh W, Manola J, Kantoff PW. Vinorelbine and estranmustine for androgen-independent prostate cancer: A Phase II Study. Cancer. In press.
Scarr RB, Smith MR, Beddall M, Sharp PA. A novel 50-kilodalton fragment of host cell factor 1 (C1) in G(0) cells. Mol Cell Biol 2000 20(10):3568-75.
Smith MR, Kaufman D. Palliation of bone metastases. In: Kantoff PW, Carroll P, D'Amico A, editors. Prostate Cancer, 1st edition. Philadelphia: Lippincott Williams and Wilkins, 2000. In press.
Smith MR, Chabner BA. Systemic chemotherapy for solid tumors. In Bland KI, Daly JM, Karakousis CP, editors. Surgical Oncology: Contemporary Principles and Practice. McGraw-Hill. In press.
Smith MR, McGovern F. Case Report: Smith MR, McGovern FJ. Gonadotropin releasing hormone (GnRH) agonist failure in a man with prostate cancer. J Urology 2001, 166(1)211.
Smith MR, McGovern F, Fallon MA, Schoenfeld D, Kantoff P, Finkelstein J. Low Bone Mineral Density in hormone nanve men with prostate cancer. Cancer, 2001;91:2238-45.
Smith MR. Bisphosphonates. In: Chabner B and Longo D, editors. Cancer Chemotherapy and Biotherapy, 3rd edition. Philadelphia: Lipincott-Raven, 2001,(24):700-706.
Kelly K, Curley T, Slovin S, McCaffrey J, Bjorin D, Ciolino A, Regan K, Schwartz M, Kantoff P, Smith MR, George D, Oh W, Kaufman D, Small E, Schwartz L, Larson, Tong W, Scher H. Paclitaxel, estramustine phosphate, and carboplatin (TEC) in patients with advanced prostate cancer. J Clin Oncol. 2001, (19)1:44-53.
Leder BZ, Smith MR, Fallon M, Lee ML, Finkelstein JS. Effects of Gonadal Steroid Suppression on Skeletal Sensitivity to Parathyroid hormone in Men (Gonadal Suppression and PTH Sensitivity). J Clin Endocrinol Metab, 2001, 86(2):511-516.
Smith MR, McGovern FJ, Zietman AL, Fallon M, Hayden DL, Schoenfeld DA, Kantoff PW, Finkelstein JS. Pamidronate to Prevent Bone Loss During Androgen Deprivation Therapy for Prostate Cancer. NEJM, 2001, 345(13):948-955.
Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon M, Schoenfeld DA, Kantoff PW. Changes in Body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab, in press.
Smith MR, Kantoff PW. Biology of prostate cancer. In: Hanks G and Hudes G, editors. Atlas of Clinical Oncology, Volume 3: Genitourinary Cancers. 2002;1:1-16.
Oh WK, Manola J, George DJ, Fierman A, Fontaine-Rothe P, Morrissey S, Prisby J, Kaufman D, Kantoff PW, Smith MR. Phase II Trial of Interferon-alpha and toremifene in metastatic renal cell cancer patients. Cancer Investigation. 2002,20(2):1-6.
Smith MR, Fuchs V, Anderson EJ, Fallon M, Manola J. Measurement of Body Fat by Dual Energy X-ray Absorptiometry (DXA) and Bioimpedance Analysis (BIA) in Men with Prostate Cancer. Nutrition, in press.
| 
